Enzymatica Publ (Sweden) Today
| ENZY Stock | SEK 4.50 0.30 6.25% |
PerformanceSolid
| Odds Of DistressBelow Average
|
Enzymatica Publ is selling for under 4.50 as of the 21st of March 2025; that is 6.25 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 4.38. Enzymatica Publ has about a 35 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. The company has 164.26 M outstanding shares. More on Enzymatica publ AB
Moving against Enzymatica Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Enzymatica Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Enzymatica Publ's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Enzymatica Publ or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chief Executive Officer | Fredrik Lindberg |
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Enzymatica publ AB (ENZY) is traded on Stockholm Exchange in Sweden and employs 23 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 681.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enzymatica Publ's market, we take the total number of its shares issued and multiply it by Enzymatica Publ's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Enzymatica publ AB operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 164.26 M outstanding shares.
Enzymatica publ AB has accumulated about 64.82 M in cash with (35.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Enzymatica Publ Probability Of Bankruptcy
Ownership AllocationEnzymatica Publ holds a total of 164.26 Million outstanding shares. Enzymatica publ AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.15 percent of Enzymatica publ AB outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Enzymatica Ownership Details
Enzymatica publ AB Risk Profiles
Although Enzymatica Publ's alpha and beta are two of the key measurements used to evaluate Enzymatica Publ's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.76 | |||
| Semi Deviation | 2.89 | |||
| Standard Deviation | 9.51 | |||
| Variance | 90.39 |
Enzymatica Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Enzymatica Publ without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Enzymatica Publ Corporate Directors
| Louise Nicolin | Director | Profile | |
| Marianne Alexandersson | Independent Director | Profile | |
| Gudmundur Palmason | Director | Profile | |
| Mats Andersson | Director | Profile |
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.